Table 2 Dosage changes in phosphate binders and cinacalcet
Phase III study (1-year study and additional 2-year study) | 5-year follow-up observational study | ||||||||
|---|---|---|---|---|---|---|---|---|---|
Dosage (mg/day) | Start (2005) | 1 year after (2006) | 2 years after (2007) | 3 years after (2008) | 4 years after (2009) | 5 years after (2010) | 6 years after (2011) | 7 years after (2012) | 8 years after (2013) |
Lanthanum carbonate | 1700.0 ± 879.4 (750–3000) (n = 30) | 1625.0 ± 966.6 (750–3750) (n = 30) | 1525.0 ± 775.0 (750–3750) (n = 30) | 1550.0 ± 834.1 (750–3750) (n = 30) | 1500 (n = 1) | 863.6 ± 452.3 (250–1500) (n = 11) | 1113.6 ± 563.1 (500–2250) (n = 11) | 970.6 ± 413.5 (250–1500) (n = 17) | 1125.0 ± 413.5 (500–1500) (n = 18) |
Calcium carbonate | – | – | – | – | 2035.7 ± 929.7 (250–3000) (n = 21) | 2133.3 ± 766.9 (1000–3000) (n = 15) | 2125.0 ± 974.7 (1000–4500) (n = 16) | 2318.2 ± 783.3 (1500–3000) (n = 11) | 1792.3 ± 950.0 (300–3000) (n = 13) |
Sevelamer hydrochloride | – | – | – | – | 1968.8 ± 1263.8 (750–4500) (n = 8) | 2035.7 ± 940.2 (750–3750) (n = 7) | 1875.0 ± 1131.9 (750–3750) (n = 10) | 1607.1 ± 1097.9 (750–3750) (n = 7) | 1821.4 ± 954.3 (750–3750) (n = 7) |
Cinacalcet hydrochloride | – | – | – | – | 40.0 ± 12.9 (25–50) (n = 10) | 44.2 ± 18.1 (25–75) (n = 13) | 41.4 ± 21.8 (25–100) (n = 16) | 42.5 ± 19.9 (25–75) (n = 15) | 39.8 ± 17.8 (25–75) (n = 16) |